trial

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

NCTId NCT04787302
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 15 (actual)
Sponsored by Cerevel Therapeutics, LLC
Primary completion 2023-07-14
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
15 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2021-06-01
Primary completion
2023-07-14
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Emraclidine

Sponsors

Cerevel Therapeutics, LLCLead Sponsor

Investigators

1
Matthew Leoni, MD, MBAStudy Director

Sites

2 total
Boston, United StatesLeuven, Belgium

Facts & assertions

4 sourced
Enrollment
15
Phase
PHASE1
Primary Completion Date
2023-07-14
Status
COMPLETED
relationships
The graph out of here
drug
Emraclidine
drug
lead_sponsor
Cerevel Therapeutics, LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Matthew Leoni, MD, MBA
person